8-K: Mirum Secures $68.5M Private Placement for Bluejay Acquisition

Mirum Pharmaceuticals announced an additional $68.5 million private placement with TCGX to fund its proposed acquisition of Bluejay Therapeutics and related clinical development.

Summary

• Mirum Pharmaceuticals, Inc. entered into a subscription agreement on December 18, 2025, with entities associated with TCG Crossover Management, LLC (TCGX) for a private placement.
• The PIPE Investors agreed to purchase 1,000,000 shares of common stock at $68.48 per share, resulting in approximately $68,480,000 in gross proceeds.
• This private placement is contingent upon the closing of Mirum's previously announced acquisition of Bluejay Therapeutics, Inc., which is expected in the first quarter of 2026.
• The proceeds from this financing, combined with a prior $200 million private placement, are intended to fund clinical development and commercial activities following the acquisition.
• A registration rights agreement was also executed, obligating Mirum to register the PIPE Shares for resale with the U.S. Securities and Exchange Commission.

Sentiment

Score: 7

Explanation: The capital raise is a positive step to fund a strategic acquisition and future development, indicating growth potential. However, it also involves shareholder dilution and is contingent on the successful closing of the acquisition, introducing some execution risk.

Positives

• Secured approximately $68.5 million in additional financing, demonstrating investor confidence and providing capital for strategic initiatives.
• Funds are specifically earmarked for clinical development and commercial activities, supporting future growth and pipeline expansion.
• The financing is a crucial step towards completing the strategic acquisition of Bluejay Therapeutics, which will expand Mirum's therapeutic focus into viral and liver diseases.
• The company has now secured a total of $268.5 million in private placements to support the Bluejay acquisition and subsequent operations.

Negatives

• The issuance of 1,000,000 new shares of common stock will result in dilution for existing shareholders.
• The closing of the private placement is contingent on the successful completion of the Bluejay acquisition, introducing execution risk.
• The shares issued in the private placement are not registered under the Securities Act of 1933 upon issuance, although a registration rights agreement is in place for future resale.

Risks

• Risks and uncertainties inherent with the acquisition of companies, including the potential for regulatory approval not to be timely received (if at all).
• Failure to satisfy or waive customary closing conditions for the proposed mergers with Bluejay Therapeutics.
• Risks and uncertainties inherent with private placements, including the successful and timely completion of the private placement itself.
• General business risks and uncertainties associated with Mirum Pharmaceuticals' operations.
• The potential impact of geopolitical and macroeconomic events on the company's business.

Future Outlook

The company anticipates the closing of the proposed mergers with Bluejay Therapeutics and the associated private placements in the first quarter of 2026. The proceeds from this financing, combined with a prior $200 million private placement, are intended to fund clinical development and commercial activities following the acquisition, supporting Mirum's strategic growth in viral and liver diseases.

Management Comments

• Mirum Pharmaceuticals, Inc. announced that it has entered into a subscription agreement with entities associated with TCGX, an institutional investor, for a private placement of 1,000,000 shares of its common stock.
• The proceeds from the private placement, together with Mirum's $200 million private placement announced earlier this month, are intended to fund clinical development and commercial activities following the previously announced proposed acquisition of Bluejay Therapeutics.

Industry Context

Mirum Pharmaceuticals, a rare disease company, is strategically expanding its pipeline through the acquisition of Bluejay Therapeutics, a biotechnology company focused on viral and liver diseases. This capital raise supports the integration and development of new assets, aligning with a common industry trend of M&A and financing to fuel growth and diversify therapeutic areas within the biotech sector.

Corporate Governance

Stakeholder Impact

• Existing shareholders will experience dilution due to the issuance of 1,000,000 new shares of common stock.
• New institutional investors (TCGX) gain a significant equity stake in Mirum Pharmaceuticals.
• The financing supports the acquisition of Bluejay Therapeutics, impacting its security holders and potentially expanding Mirum's employee base and therapeutic offerings.
• Customers and patients may benefit from accelerated clinical development and commercialization of new medicines in viral and liver diseases.

Next Steps

• Closing of the proposed mergers with Bluejay Therapeutics, Inc. in the first quarter of 2026.
• Closing of the private placement concurrently with the mergers.
• Preparation and filing of a registration statement with the SEC to register the resale of the PIPE Shares.
• Funding of clinical development and commercial activities post-acquisition.

Key Dates

Recommendation

The private placement provides crucial funding for a strategic acquisition and future growth initiatives, which is a positive long-term signal. However, the immediate impact includes shareholder dilution, and the success of the investment hinges on the effective integration of Bluejay Therapeutics and the successful development of its pipeline. Given these balanced factors, a 'hold' recommendation is appropriate for investors to observe the execution of the acquisition and subsequent development activities.

Keywords

Mirum Pharmaceuticals, MIRM, Private Placement, Capital Raise, Bluejay Therapeutics, Acquisition, Merger, Biotechnology, Rare Disease, TCGX, Equity Financing, SEC Filing, 8-K